Since its development, tariquidar (XR9576, TQR) has been widely regarded as one of the more potent inhibitors of P-glycoprotein (P-gp), an efflux transporter of the ATP-binding cassette (ABC) transporter family. A third-generation inhibitor, TQR exhibits high affinity for Pgp, although it is also a substrate of another ABC transporter, breast cancer resistance protein (BCRP). Recently, several studies have questioned the mechanism by which TQR interfaces with P-gp, suggesting that TQR is a substrate for P-gp instead of a noncompetitive inhibitor. We investigated TQR and its interaction with human and mouse P-gp to determine if TQR is a substrate of P-gp in vitro. To address these questions, we used multiple in vitro transporter assays including cytotoxicity, flow cytometry, accumulation, ATPase, and transwell assays. A newly generated BCRP cell line was used as a positive control that demonstrates TQR-mediated transport. Based on our results, we conclude that TQR is a potent inhibitor of both human and mouse P-gp and shows no signs of being a substrate at the concentrations tested. These in vitro data further support our position that the in vivo uptake of [ 11 C]TQR into the brain can be explained by its high affinity binding to P-gp and by it being a substrate of BCRP, followed by amplification of the brain signal by ionic trapping in acidic lysosomes.
Introduction
The ATP-binding cassette (ABC) transporters have a profound impact on therapeutic efficacy. These transmembrane transporters use ATP to pump small molecules out of cells, irrespective of the concentration gradient (Gottesman et al., 2002) . As a result, expression of family members such as P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) at sites such as the blood-brain barrier (BBB) or in multidrug-resistant (MDR) tumors can reduce drug accumulation (Gottesman et al., 2002; Loscher and Potschka, 2005) . A number of small-molecule inhibitors of P-gp were developed with the intention of reversing the efflux of chemotherapeutics from MDR cancer cells. Early ('first-generation') inhibitors were existing pharmaceutics already known to inhibit P-gp such as verapamil and cyclosporine A (CsA). Second-generation inhibitors were simple derivatives of first-generation inhibitors lacking their primary pharmacologic activity. Subsequent medicinal chemistry efforts led to new chemical compounds known as third-generation high-affinity (nanomolar IC 50 s) P-gp inhibitors.
In clinical trials however, inhibitors did not improve patient outcome, although there were some notable exceptions (Tamaki et al., 2011; Shaffer et al., 2012) . More recently, P-gp inhibitors have been utilized in humans as part of positron emission tomography (PET) imaging in combination with radiolabeled substrates of P-gp in order to measure the function of the transporter at the BBB (Kannan et al., 2009; Mairinger et al., 2011) .
hamster ovary (CHO) cells expressing hamster P-gp indicated that TQR inhibited the transporter by blocking ATPase activity, and that TQR was not a substrate for P-gp (Martin et al., 1999) .
That report established the prevailing view on the mechanism of action of TQR, and subsequent work confirmed that [ 3 H]TQR was not effluxed as a substrate from human P-gp-expressing cells (Kannan et al., 2011) .
Several recent studies have contradicted earlier data and questioned the interaction of TQR with P-gp. First, Loo et al. reported that TQR stimulated the ATPase activity of a 'Cysless' mutant form of human P-gp (Loo and Clarke, 2014) . Second, two simultaneously published papers reported that in PET studies with [ 11 C]TQR, only mice genetically lacking both BCRP and P-gp exhibited brain penetration of [ 11 C]TQR as compared to mice lacking either BCRP or P-gp (Bauer et al., 2010; Kawamura et al., 2010) . Third, Bankstahl et al. reported that in a transwell apparatus, cells expressing mouse or human P-gp accumulated more [ 3 H]TQR in the presence of the P-gp inhibitor PSC833 (Bankstahl et al., 2013) . These results are more consistent with TQR behaving like a substrate of P-gp.
Given that earlier studies could not detect that TQR was a substrate of P-gp, we hypothesized that species differences may account for the divergent observations that exist in the literature. To this end, we assessed TQR's interaction with human and mouse P-gp, utilizing techniques regularly employed for assessing transporter interactions, with BCRP serving as a positive control. This included radiation and flow cytometry accumulation assays, ATPase assays in crude membranes, and cytotoxicity assays measuring the ability of TQR to inhibit P-gp.
Finally, we generated an LLC-PK1 cell line expressing BCRP and assessed the transwell transport of TQR by polarized cells expressing P-gp or BCRP. Confirming the relationship
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, glutamine, and antibiotic.
All LLC PK1 porcine kidney cell lines were grown in CA) supplemented with 3% fetal bovine serum, glutamine, antibiotic, 500 μg/ml G418 (for LLCvector, LLC-EQ, and LLC-MDR1-WT cells, hereafter referred to as LLC-MDR1) or 500 μg/mL zeocin (for LLC-BCRP-vector and LLC-BCRP cell lines). For all cell cultures, medium was removed and cells were grown in the same medium in the absence of drug selection 5 to 30 days before assays.
Generation of LLC-BCRP Cell Line. LLC-PK1 cells expressing human ABCG2 were generated by transient DNA transfection of LLC-PK1 cells (Fung et al., 2014a) , with plasmids containing human ABCG2 cDNA (SAIC, Frederick, MD) and vector alone using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. After transfection, stable cells were isolated by colony cloning. At least 30 individual clones were isolated and were constantly selected by zeocin (500 μg/mL) for 2 weeks for further analysis.
Cytotoxicity Assay. Cytotoxicity assays were performed to determine the ability of TQR to reverse the resistance of human and mouse P-gp to the cytotoxic substrate paclitaxel. The same assay was used to verify the presence of functional BCRP in the LLC-BCRP cells. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay. Cells were seeded at a density of 4,000 cells per well in 100 μ L of media. Serial dilutions of either paclitaxel or MTX (for LLC-BCRP cells) were made in DMEM, and an additional 100 μ L of media containing inhibitor was added to each well (TQR for P-gpexpressing cells and Ko143 for LLC-BCRP cells). The outcome measure was half maximal inhibitory concentration (IC 50 ), which indicates the concentration of cytotoxic drug required to
decrease cell viability by 50% compared to untreated control cells (Brimacombe et al., 2009 ).
The resistance ratio (RR) was then calculated from three separate experiments by dividing the mean IC 50 of the resistant cell line by that of the parental cell line's IC 50 .
Flow Cytometry. Flow cytometry was used to measure the activity of P-gp in the presence of TQR, as well as measure the fluorescence of TQR itself, and confirm cell surface expression of BCRP on the newly generated LLC-BCRP cell line. The experiments were conducted as previously described (Weidner et al., 2015) with the following modifications. The Germany) with a C-Apochromat 40x objective lens. For TQR and Lysotracker Red, excitation wavelengths were 355 nm (with a UV laser) and 561 nm, and fluorescence emission spectral detector windows were set at 420-550 nm and 585-690 nm, respectively. Images were acquired with an optical slice thickness of 1.0 μm and 0.10 μm X-Y pixel size. added to parent and P-gp-expressing cells with and without the addition of 1 μ M cold TQR. Six wells received non-radioactive media to account for background signal, while another six were reserved for cell counts in order to standardize accumulation. Cells were incubated in radioactive media for 30 min at 37 °C. Media was then removed, cells were washed in phosphate buffered solution (pH 7.4) and 100 µL of trypsin was added to each well for 90 min. Radioactivity was then measured using a liquid scintillation counter. After correction for cell counts, radioactivity was expressed as percent accumulation compared to untreated control cells.
ATPase Assays. To determine whether TQR affects human and mouse P-gp differently,
ATPase assays were performed using crude membrane extracts from High-five insect cells expressing either human or mouse P-gp. Due to the fact that wild-type mouse mdr1a cDNA is toxic in the bacterial cells needed for the cloning process, a M107L point mutation was introduced, which reduced bacterial toxicity but retained functionality (Pluchino et al., 2015) .
The protocol described in Kannan et al. (2011) was followed. Briefly, the membrane vesicles in ATPase assay buffer (50 mM MES-Tris buffer (pH 6.8), 50 mM KCl, 5 mM sodium azide, 1 mM EGTA, 1 mM ouabain, 10 mM MgCl 2 , and 2 mM DTT) were incubated in varying concentrations of TQR with or without 0.3 mM sodium orthovanadate. ATP hydrolysis was measured by estimating the release of inorganic phosphate after incubation with 5 mM ATP as described previously (Shukla et al., 2006) .
Protein Extraction and Immunoblot Analysis.
Total protein extraction from cell culture and protein concentration estimation methods were reported previously (Fung et al., 2014b) . For SDS-PAGE, protein samples were loaded onto a 3-8% Tris-acetate gel (Invitrogen). 
Results
Tariquidar as an Inhibitor of P-gp. We first examined whether TQR was equally effective as an inhibitor of mouse and human P-gp. Using MTT cytotoxicity assays, we determined the effect of increasing TQR concentrations on cells expressing human and mouse P-gp (C3M) by measuring the sensitization of these cell lines to the P-gp-specific cytotoxic substrate, paclitaxel. The IC 50 of paclitaxel significantly decreased in the presence of 10 nM (P < 0.01), 100 nM (P < 0.001), and 1 μM (P < 0.001) TQR in cells expressing human Pgp compared to cells treated with paclitaxel alone (Table 1 ). In cells expressing mouse P-gp, the IC 50 decreased after 100 nM and 1 μM TQR (both P < 0.001) ( Table 1 ). The disparity in response can be attributed to the inherent differences between human and mouse P-gp, as well as the basal P-gp expression in the mouse parental 3T3 cells. Treatment with 1 nM TQR had no effect on cellular sensitivity to paclitaxel. We also determined the inherent cytotoxicity of TQR and found the IC 50 value to be 50 µM in human and mouse cells irrespective of P-gp expression (data not shown).
The ability of TQR to inhibit P-gp was also measured via accumulation of the fluorescent P-gp substrate Rh123 using flow cytometry. While the co-incubation of 10 nM TQR had no effect on accumulation of Rh123, 100 nM restored accumulation of Rh123 in cells expressing human P-gp to that of the parent cells (P < 0.0001; Fig. 1A ). Concentrations of TQR from 10 -
concentrations (1 and 10 μM TQR, Fig. 1A ), and the effect was also observed in the parental KB-3-1 cells (Fig. 1C) . Given that Rh123 is a mitochondrial dye, it is possible that TQR accumulates in the mitochondria at higher concentrations, depolarizing and displacing Rh123.
We previously reported a similar effect for TQR in lysosomes (Kannan et al., 2011) .
Interactions of TQR With P-gp. Having established that TQR inhibits mouse and human P-gp, we next examined the interaction of P-gp with TQR to determine whether we could observe any substrate-like interaction between TQR and P-gp. In a previous report, we found that KB-8-5-11 cells expressing human P-gp bound more [ 
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Given the inherent fluorescence of TQR, we were able to examine its uptake directly using confocal microscopy (ex = 420 nm, em = 550 nm). In KB-3-1 cells, TQR fluorescence is observed as punctate staining (Fig. 4A , green, top left). We have previously reported that TQR is a weak base that competes with other weak bases for lysosomal trapping, and the fluorescent lysosome stain Lysotracker Red also demonstrates punctate staining (Fig. 4A , red, top right) that co-localizes with TQR ( Fig 4A, merge, bottom left) . P-gp-expressing cells demonstrate similar accumulation of TQR with no qualitative difference in accumulation observable (not shown). To identify a concentration of TQR appropriate for assessing cellular accumulation by flow cytometry, we assessed increasing concentrations of TQR in KB-3-1 cells, and found that the geometric mean of fluorescence was positively correlated to concentration (Fig. 4B) , and detectable at 20 μM. We then compared the uptake of TQR in cells expressing either human Pgp or BCRP before and after transporter inhibition as well as to the uptake of positive control fluorescent substrates of P-gp and BCRP (Fig. 4C) . In KB-8-5-11 cells, there was no difference in TQR fluorescence before and after inhibition with CsA, whereas there was a marked difference in the uptake of the P-gp substrate, Rh123, under the same conditions (P < 0.001). In cells expressing human BCRP (MCF7 FLV10000), the accumulation of TQR increased after incubation with Ko143 (P < 0.001), consistent with its characterization as a BCRP substrate. A strong effect was observed for the positive control BCRP substrate Pp-18 under the same conditions (P < 0.0001). we generated an LLC-PK1 cell line transfected with human BCRP (termed LLC-BCRP). To confirm the expression of BCRP in the newly-generated LLC-BCRP line, a Western blot was performed using two monoclonal anti-BCRP antibodies. We found expression of BCRP in the LLC-BCRP cell line, but not in LLC-vector cells (cell lysate from a BCRP-expressing cell line was used as a positive control in lane 1) (Fig. 5A) . Cell surface immunolabeling with a 5D3-PE anti-BCRP antibody was used to assess the cell surface expression of BCRP, which showed increased expression in the LLC-BCRP cells compared to the LLC-vector cells (Fig. 5B) . To determine functionality, flow cytometry experiments with the fluorescent BCRP substrate PPA were conducted, which showed that BCRP-mediated efflux was reversed in the presence of Ko143 (Fig. 5C ). MTT cytotoxicity assays mirrored these results; the LLC-BCRP cells were resistant to MTX (IC 50 = 9.8 µM) compared to LLC-vector (IC 50 = 2.2 µM). Resistance in the LLC-BCRP line was reversed in the presence of Ko143 (IC 50 = 1.0 µM; Fig. 5D ).
The susceptibility of compounds to be transported by P-gp or BCRP can be assessed using transporter-expressing polarized LLC-PK1 cells grown in permeable transwell filters (Taub et al., 2005) . Consistent with the fact that TQR is a substrate of BCRP (Kannan et al., 2011) , the basolateral to apical transport of [ 3 H]TQR was significantly higher than in the apical to basolateral direction with LLC-BCRP cells (Fig. 6 , Table 2 ). The addition of inhibitors Ko143
(1 µM) or elacridar (10 µM) resulted in equal concentrations of [ 3 H]TQR on either side (Fig. 6 , 
Discussion
Despite the minimal literature on the interaction of TQR with P-gp, there exists confusion in the field as to whether TQR is a non-transported inhibitor or a substrate of P-gp. Using multiple in vitro assays and a range of concentrations, our results clearly show that TQR is an effective inhibitor of both human and mouse P-gp in vitro, consistent with a similar characterization using hamster P-gp reported by Martin et al. (1999) . None of the methods employed provided any indication that TQR is a substrate of P-gp, whereas we have provided additional evidence that TQR is a substrate of BCRP.
The interaction of TQR with P-gp has been previously examined in several ways. There The primary study on the mechanism of TQR is that of Martin et al., who of 5.1 nM (n = 7), a rapid association rate (10 times faster than vinblastine), and a slow dissociation rate. It is noteworthy that the experimental replicates were numerous -TQR is highly lipophilic with a clogP of 6.1 (Egger et al., 2007) , and this causes high binding to plastic and the need for a large number of replicates (Callaghan, 2013 -displacement is observed in P-gp-expressing cells, but TQR is elevated in parental cells to parity with the P-gp expressing cells (Fig. 2) . We believe this is related to high levels of 'cold'
TQR that block binding sites on plastic and elevate the free (non-plastic-bound) fraction of hydrolysis. This effect has not been observed in our work with wild-type human or M107L P-gp.
We examined TQR using other transporter assays in an attempt to tease out possible TQR-P-gp substrate interactions. By utilizing TQR's inherent fluorescence, we were able to directly measure its uptake into cells using flow cytometry (Fig. 4B) . No change in the efflux of TQR was observed with inhibitor, though in cells expressing BCRP, TQR behaved as a weak substrate (Fig. 4C) . We also conducted transwell assays using [ 3 H]TQR in LLC-PK1 cells transfected with human P-gp or BCRP. The LLC-BCRP cells were generated in this study (Fig.   5 ), while the LLC-MDR1, LLC-vector, and LLC-EQ cells have previously been characterized (Fung et al., 2014a; Fung et al., 2014b) . While BCRP-transfected cells transported [ 3 H]TQR, Pgp and vector-transfected cells did not (Fig. 6 , Table 2 ).
Two PET studies using [ address below. We have found the opposite effect for TQR accumulation in P-gp-expressing cells (this study) using several different cell-based assays.
We have previously described the possible behavior of a radiolabeled P-gp inhibitor in vivo (Kannan et al., 2013) , and the data outlined in this study further support our position. P-gp and BCRP have distinct mechanisms to block brain uptake of TQR: P-gp binds TQR, whereas BCRP transports it. Both of these mechanisms (binding and transport) have some spare capacity relative to the low concentrations of [ 
